Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492.
   PubMed Web of Science ®Google Scholar
• Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490–1502. doi: 10.1016/S0140-6736(13)61649-9.
   PubMed Web of Science ®Google Scholar
• Venook AP, Niedzwiecki D, Lenz H, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer. JAMA. 2017;317(23):2392–2401. doi: 10.1001/jama.2017.7105.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–1422. doi: 10.1093/annonc/mdw235.
   PubMed Web of Science ®Google Scholar
• Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the gruppo oncologico nor. J Clin Oncol. 2007;25(13):1670–1676. doi: 10.1200/JCO.2006.09.0928.
   PubMed Web of Science ®Google Scholar
• Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a: multicentre randomised phase III trial from the hellenic oncolog. Br J Cancer. 2006;94(6):798–805. doi: 10.1038/sj.bjc.6603011.
   PubMed Web of Science ®Google Scholar
• Gruenberger T, Bridgewater J, Chau I, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol. 2015;26(4):702–708. doi: 10.1093/annonc/mdu580.
   PubMed Web of Science ®Google Scholar
• Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371(17):1609–1618. doi: 10.1056/NEJMoa1403108.
   PubMed Web of Science ®Google Scholar
• Maniadakis N, Pallis A, Fragoulakis V, et al. Economic analysis of a multicentre, randomised, phase III trial comparing FOLFOXIRI with FOLFIRI in patients with metastatic colorectal cancer in Greece. Curr Med Res Opin. 2007;23(9):2251–2257. doi: 10.1185/030079907X223765.
   PubMed Web of Science ®Google Scholar
• Sen C, Khanna S, Rink C, et al. Tocotrienols: the emerging face of natural vitamin E. Vitam Horm. 2007;76:203–261.
   PubMed Web of Science ®Google Scholar
• Husain K, Centeno B, Chen D-T, et al. Vitamin E δ-tocotrienol prolongs survival in the LSLKrasG12D/+; LSL-Trp53R172H/+;pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer. Cancer Prev Res (Phila). 2013;6(10):1074–1083. doi: 10.1158/1940-6207.CAPR-13-0157.
   PubMed Web of Science ®Google Scholar
• Cardenas E, Ghosh R. Vitamin E: a dark horse at the crossroad of cancer management. Biochem Pharmacol. 2013;86(7):845–852. doi: 10.1016/j.bcp.2013.07.018.
   PubMed Web of Science ®Google Scholar
• Aggarwal BB, Sundaram C, Prasad S, et al. Tocotrienols, the vitamin E of the 21st century: it’s potential against cancer and other chronic diseases. Biochem Pharmacol. 2010;80(11):1613–1631. doi: 10.1016/j.bcp.2010.07.043.
   PubMed Web of Science ®Google Scholar
• Boyette-Davis JA, Hou S, Abdi S, et al. An updated understanding of the mechanisms involved in chemotherapy-induced neuropathy. Pain Manag. 2018;8(5):363–375. doi: 10.2217/pmt-2018-0020.
   PubMed Web of Science ®Google Scholar
• Sailo BL, Banik K, Padmavathi G, et al. Tocotrienols: the promising analogues of vitamin E for cancer therapeutics. Pharmacol Res. 2018;130:259–272. doi: 10.1016/j.phrs.2018.02.017.
   PubMed Web of Science ®Google Scholar
• Nesaretnam K, Selvaduray KR, Abdul Razak G, et al. Effectiveness of tocotrienol-rich fraction combined with tamoxifen in the management of women with early breast cancer: a pilot clinical trial. Breast Cancer Res. 2010;12(5):R81. http://breast-cancer-research.com/content/12/5/R81. doi: 10.1186/bcr2726.
   PubMed Web of Science ®Google Scholar
• Springett GM, Husain K, Neuger A, et al. A phase I safety, pharmacokinetic, and pharmacodynamic presurgical trial of vitamin E δ-tocotrienol in patients with pancreatic ductal neoplasia. EBioMedicine [Internet]. 2015;2(12):1987–1995. doi: 10.1016/j.ebiom.2015.11.025.
   PubMed Web of Science ®Google Scholar
• Thomsen CB, Andersen RF, Steffensen KD, et al. Delta tocotrienol in recurrent ovarian cancer. A phase II trial. Pharmacol Res. 2019;141:392–396. doi: 10.1016/j.phrs.2019.01.017.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi: 10.1016/j.ejca.2008.10.026.
   PubMed Web of Science ®Google Scholar
• Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. doi: 10.1016/j.jbi.2008.08.010.
   PubMed Web of Science ®Google Scholar
• Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi: 10.1016/j.jbi.2019.103208.
   PubMed Web of Science ®Google Scholar
• Masi G, Allegrini G, Cupini S, et al. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol. 2004;15(12):1766–1772. doi: 10.1093/annonc/mdh470.
   PubMed Web of Science ®Google Scholar
• Rubinstein LV, Korn EL, Freidlin B, et al. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol. 2005;23(28):7199–7206. doi: 10.1200/JCO.2005.01.149.
   PubMed Web of Science ®Google Scholar
• Esfahani A, Somi M h, Ayromlou H, et al. The effect of n-3 polyunsaturated fatty acids on incidence and severity of oxaliplatin induced peripheral neuropathy: a randomized controlled trial. Biomark Res. 2016;4:13. doi: 10.1186/s40364-016-0066-3.
   PubMedGoogle Scholar
• Trinh T, Park SB, Murray J, et al. Neu-horizons: neuroprotection and therapeutic use of riluzole for the prevention of oxaliplatin-induced neuropathy—a randomised controlled trial. Support Care Cancer. 2021;29(2):1103–1110. doi: 10.1007/s00520-020-05591-x.
   PubMed Web of Science ®Google Scholar
• Zedan AH, Hansen TF, Svenningsen ÅF, et al. Oxaliplatin-induced neuropathy in colorectal cancer: many questions with few answers. Clin Colorectal Cancer. 2014;13(2):73–80. doi: 10.1016/j.clcc.2013.11.004.
   PubMed Web of Science ®Google Scholar
• O. Heinonen DA. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330(15):1029–1035. doi: 10.1056/NEJM199404143301501.
   Web of Science ®Google Scholar
• Kunnumakkara AB, Sung B, Ravindran J, et al. γ-Tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment. Cancer Res. 2010;70(21):8695–8705. doi: 10.1158/0008-5472.CAN-10-2318.
   PubMed Web of Science ®Google Scholar
• Tomasello G, Petrelli F, Ghidini M, et al. FOLFOXIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. JAMA Oncol. 2017;3(7):e170278. doi: 10.1001/jamaoncol.2017.0278.
   PubMed Web of Science ®Google Scholar
• Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306–1315. doi: 10.1016/S1470-2045(15)00122-9.
   PubMed Web of Science ®Google Scholar
• Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up ⋆. Ann Oncol. 2023;34(1):10–32. doi: 10.1016/j.annonc.2022.10.003.
   PubMed Web of Science ®Google Scholar
• Colon Cancer Colon Cancer. NCCN Clin Pract Guidel Oncol (NCCN Guidel [Internet]. 2023;Version 1. Available from: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
   Google Scholar
• Inokuchi H, Hirokane H, Tsuzuki T, et al. Anti-angiogenic activity of tocotrienol. Biosci Biotechnol Biochem. 2003;67(7):1623–1627. doi: 10.1271/bbb.67.1623.
   PubMed Web of Science ®Google Scholar
• Weng-Yew W, Selvaduray KR, Ming CH, et al. Suppression of tumor growth by palm tocotrienols via the attenuation of angiogenesis. Nutr Cancer. 2009;61(3):367–373. doi: 10.1080/01635580802582736.
   PubMed Web of Science ®Google Scholar
• Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249(3):420–425. doi: 10.1097/SLA.0b013e31819a0486.
   PubMed Web of Science ®Google Scholar
• Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability study. Neurology. 1999;53(8):1660–1664. doi: 10.1212/wnl.53.8.1660.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Jann S, Pace A, et al. Multi-center assessment of the total neuropathy score for chemotherapy-induced peripheral neurotoxicity. J Peripher Nerv Syst. 2006;11(2):135–141. doi: 10.1111/j.1085-9489.2006.00078.x.
   PubMed Web of Science ®Google Scholar